Menu ×


VEGF Inhibitor Drugs Market Segmentation By Target (VEGF-A, VEGF-B, VEGF-C, VEGF-D and Others); By Inhibitor (Tyrosine Kinase Inhibitors, Monoclonal Antibodies and VEGFR Hybrids); By Application (Oncology, Ophthalmology and Others); By Distribution Channel (Retail Pharmacies, Online Pharmacies and Hospital Pharmacies) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • On October 8, 2019, Novartis announced that it received approval from the U.S. Food and Drug Administration (FDA) for its Beovu® (brolucizumab) injection, which is also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). This drug is offers a higher fluid resolution as compared with aflibercept along with the ability to keep eligible patients on a 3-month long dosing interval after a 3-month loading phase with uncompromised efficacy, and is the first FDA approved anti-VEGF to do so.

Introduction to VEGF Inhibitor Drugs

Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells. This growth factor plays an important role in the survival of various forms of tumor as it induces tumor angiogenesis. VEGF inhibitors are the chemicals which restrict the functioning of these vascular endothelial growth factors, thereby preventing any further cancer growth and eventually treating the condition. VEGF inhibitor can be produced in the form of drugs and can be used as an effective cancer therapy.

Market Size and Forecast

The VEGF inhibitor drugs market is anticipated to record a CAGR of around 9% over the forecast period, i.e., 2020-2028. The market is segmented by target, by inhibitor, by application, by distribution channel and region, out of which, the target segment is further segmented into VEGF-A, VEGF-B, VEGF-C, VEGF-D and others. The market for VEGF-A is anticipated to hold the largest share in the VEGF inhibitor drugs market on account of VEGF-A being responsible for inducing angiogenesis as well as regulating the cell division in endothelial cells.

On the basis of application, the market is segmented into oncology, ophthalmology and others, out of which, the segment for oncology is predicted to grow at the highest rate over the forecast period. This can be attributed to the rising cases of cancer globally, along with the increasing demand for effective cancer therapies which result in minimum side effects. The Centers for Disease Control and Prevention estimated the number of new cancer cases to increase by around 24% among men between 2010 and 2020 and by about 21% among women during the same period in the United States.

VEGF Inhibitor Drugs Market Graph

Growth Drivers

Rising Cases of Cancer to Boost the Market Growth

As per the World Health Organization, cancer is the second leading cause of death worldwide. It was predicted to cause about 9.6 million deaths in 2018. Further, approximately 1 in every 6 deaths is caused as a result of cancer. It has been observed that the number of cases of cancer are rising at a significantly high rate, which is predicted to continue to grow further in the coming years. On the back of this, the market for VEGF inhibitor drugs is anticipated to grow by the end of 2028. CLICK TO DOWNLOAD SAMPLE REPORT

Growing Demand for Monoclonal Antibodies as Therapy to Drive the Market Growth

The research and development on monoclonal antibodies for the purpose of developing various treatment methods is estimated to be a major growth factor for the market. Moreover, the rising demand for combination therapies on account of their higher effectiveness than monotherapy drugs, especially in the case of various cancers, the market is anticipated to witness a huge growth opportunity.


High Cost of VEGF Inhibitor Drugs to Restrict the Market Growth

As the market for VEGF inhibitor drugs is currently of a moderate size, there is limited availability of these drugs in the market. Moreover, this results in the drugs being expensive and not affordable for the middle and lower class in various countries. In addition to this, the side effects associated with the use of VEGF inhibitor drugs are predicted to be another growth restricting factor for the market.

Market Segmentation

Our in-depth analysis of the VEGF inhibitor drugs market includes the following segments:

By Target

  • VEGF-A
  • VEGF-B
  • VEGF-C
  • VEGF-D 
  • Others

By Inhibitor

  • Tyrosine Kinase Inhibitors
  • Monoclonal Antibodies
  • VEGFR Hybrids

By Application

  • Oncology
  • Ophthalmology
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

By Region

On the basis of regional analysis, the VEGF inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is anticipated to hold the leading share globally as a result of rising investments by government and private entities in research and development of cancer therapies and treatments, including VEGF inhibitor drugs. According to the American Cancer Society, more than 1.8 million new cases are estimated to be diagnosed in the United States in 2020. Further, around 606,520 people in the region are predicted to die of cancer, i.e., about 1,660 deaths every day in the same year. Moreover, the growing elderly population in the region is another factor estimated to contribute towards the increasing demand for novel therapies in the market.

VEGF Inhibitor Drugs Market segmentation image

The VEGF inhibitor drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved